Local Clinical Trials in Beijing, Beijing Municipality
45 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 45 trials
Recruiting
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Locally Advanced Rectal Cancer (LARC)
Beijing Friendship Hospital60 enrolled1 locationNCT07393048
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Colorectal, CancerEsophageal CancerOvarian Cancer+12 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled15 locationsNCT07066657
Recruiting
Phase 1Phase 2
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Locally Advanced or Metastatic Pancreatic Cancer With
Shanghai Hengrui Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07296341
Recruiting
Phase 1Phase 2
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Unresectable Locally Advanced or Metastatic Melanoma
Shanghai JMT-Bio Inc.188 enrolled1 locationNCT07280832
Recruiting
Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting
Not Applicable
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting
Phase 2
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Locally Advanced Colorectal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences170 enrolled3 locationsNCT06154538
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.460 enrolled60 locationsNCT06680921
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 3
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
BeBetter Med Inc330 enrolled1 locationNCT06998108
Recruiting
Phase 2Phase 3
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital120 enrolled1 locationNCT06907602
Recruiting
Phase 2
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Circulating Tumor DNALocally Advanced Rectal Carcinoma
Peking Union Medical College Hospital470 enrolled1 locationNCT05601505
Recruiting
Phase 2
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
HER2-positive Locally Advanced Resectable Gastric Cancer
Peking University18 enrolled1 locationNCT06023758
Recruiting
Phase 3
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd486 enrolled1 locationNCT06177041
Recruiting
Phase 1Phase 2
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Non-small Cell Lung CancerLocally Advanced or Metastatic Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.360 enrolled1 locationNCT04996121